MGLL and breast carcinoma: These data are in line with observations in melanoma, ovarian and breast cancer cells, where knockdown of MAGL via transfection of shRNA but not pharmacological inhibition of MAGL with JZL184 decreased cellular viability, implying that long-term inhibition of MAGL may be necessary for this effect [18].